title: Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.
authors.forename: Jan
authors.initials: J
authors.lastname: Kunkel
authors.forename: Christoph
authors.initials: C
authors.lastname: Loddenkemper
authors.forename: Zarko
authors.initials: Z
authors.lastname: Grozdanovic
authors.forename: Karsten
authors.initials: K
authors.lastname: Schulze
authors.forename: Alexander
authors.initials: A
authors.lastname: Schmittel
authors.forename: Hans-Jörg
authors.initials: HJ
authors.lastname: Epple
authors.forename: Severin
authors.initials: S
authors.lastname: Daum
authors.forename: Martin
authors.initials: M
authors.lastname: Zeitz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D000093542:Gemcitabine
chemical_list: D011799:Quinazolines; D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; D000093542:Gemcitabine